| Feb 22, 2012
Transdermal medical device specialist Echo Therapeutics has developed a deep expertise in advanced skin permeation technology. The company has developed the Symphony ® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude ® SkinPrep System for transdermal drug delivery. It has just announced that it is initiating clinical studies of its system in critical care patients. The company expects to complete and announce the results of the studies in the near term.
Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.
Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
The two component glucose monitoring system incorporates skin prep using the Prelude device to remove the outer skin layer in an atraumatic fashion, following which the Symphony Monitor is brought into contact with the lightly derma braded skin. The device monitors for up to 24 hours, although a 48 hour version is apparently in the pipeline.
Watch video: Here
Read more: Here
